She also completed an internship at The Record newspaper in North Jersey last summer. Nonetheless, the experiences were invaluable, said Furst, who last year served as editor-in-chief at TCNJ’s award-winning student newspaper, The Signal. The internship at CNN was remote due to coronavirus restrictions, as was another she did earlier in the year at an NBC affiliate in Washington D.C. I get to learn constantly while I’m on the job, and that might be my favorite part about journalism,” she says. “Every time you report on an area, you learn more about its community and experience. ![]() 2 spot on Apple News’ “Trending News” list. A widely read story about a rare and colorful 100-pound opah “moonfish” that washed up on the Oregon coast in July made it to the No. “It was a story I’ll never forget.”īut there was also time for the offbeat and fun. There were times it was tiring, both physically and emotionally. “I have never worked on such a big story, and for weeks on end, in my career before. “ Each day when I signed on, I never knew what state or region I’d be reporting on,” explains the journalism and professional writing major.Įarly in her stay at CNN, Furst spent a good deal of time reporting remotely on the condominium collapse in Surfside, FL, talking to experts and survivors of the tragedy that dominated headlines for weeks. The news cycle can be relentless, but for Camille Furst ’22, it’s also incredibly rewarding.įurst, who interned on CNN’s national news desk this summer reporting on stories from across the country, says one of her favorite parts of working the desk was learning about the make up of America. In a clinical trial published in the New England Journal of Medicine last year, people who were overweight or obese, but did not have diabetes, lost an average of 52 pounds on the highest dose of the drug, or more than 20% of their starting weight.Camille Furst ’22 is a storyteller - and a story finder. There has already been a lot of buzz about tirzepatide’s potential as an obesity medication. That shortage then rippled into shortages for diabetes patients as doctors began prescribing other diabetes medications off-label for weight loss. High demand, coupled with manufacturing problems, threw Wegovy into shortage for much of the last year. When prescribed for diabetes, the injection is sold under the brand name Ozempic. When prescribed for weight loss, it is sold under the brand name Wegovy. Semaglutide, manufactured by Novo Nordisk, has also been approved as a weight loss medication for overweight adults with at least one associated health problem since 2021. WHO advisers to consider whether obesity medication should be added to Essential Medicines List ![]() Like other drugs in its class, it also seems to help people lose substantial amounts of weight. In clinical trials, people who took tirzepatide experienced more nausea, vomiting and diarrhea compared with those who took a placebo injection. It also slows down the movement of food from the stomach, making people feel fuller for longer. When blood sugar rises after eating, the drug stimulates the body to produce more insulin, which lowers blood sugar. Tirzepatide works by mimicking the action of two different gut hormones. The shortages made the medications difficult for patients with diabetes to get. Tirzepatide, along with several similar types of drugs taken for diabetes, went into shortage last year as success stories posted on social media fueled runaway demand for their weight loss benefits. Gudzune points out that once a drug is FDA approved it can be prescribed for any reason a doctor sees as medically necessary. Jeremy Mitchell and family Courtesy Jeremy MitchellĪs the market for new weight loss drugs soars, people with diabetes pay the price
0 Comments
Leave a Reply. |